Despite widespread epidemiological attention to surveillance for adverse drug reactions (ADR's), the results of surveys remain difficult to interpret because identification of ADR's has been a non-reproducible act of unspecified, subjective judgment.
261
col., Minneapolis, Minnesota.
Despite extensive clinical use, the basis for the antihypernsive action of alpha-methyldopa (a-MD) has remained undefined. pha-methyldopamine (a-MDA), the decarboxylated product of a-MD, as been suggested as a possible mediator of these effects in the NS. A sensitive and specific high-pressure liquid chromatographc system coupled to an electrochemical detector has been develped for the assay of a-MD, its metabolites and their sulfated onjugates in biological specimens. This technique has routinely etected 0.1 ug/ml of aromatic amine. In 7 hypertensive pediatric atients receiving a-MD therapy, the serum levels of a-MD and its -0-SO4 onj jug ate were significantly elevated in subjects with mpaired renal function (creatinine>2.0). The presence of a-MDA nd its 3-0-SO4 conjugate has also been demonstrated in serum. n renal dysfunction there is a 6-10 fold elevation of both a-MD nd its sulfated conjugate. The ratio a-MDA-3-0-S04:a-MDA (7-10) s significantly higher than the comparable a-MD-3-0-S04:a-MD atio (2-4) in all patients. Phenobarbital has long been the drug of choice in controlling seizures and narcotic abstinence syndrome (NAS) in newborns. This report describes the relationship between dosage and serum concentration using a high oral loading dose of phenobarbital followed by maintenance dosing to provide therapeutic serum levels more rapidly than with previous methods. Twenty neonates born to narcotic dependent mothers were studied; all had NAS anc were evaluated by an abstinence scoring system. When high abstinence scores were reported (>a), all received a loading dose of 16 mg/kg of phenobarbital orally to rapidly achieve an expected therapeutic serum level of 18 mcgfml. Results showed a serum level of 16 mcglml 2 2.6 at 3 hours after the loading dose as determined by the EMIT technique. Serum levels (mcglml) at 12 and 24 hours after the loading dose were 18.9 + 3 and 18.6 + 3.L If the infant responded with the expected therapeutic serum level, and if the abstinence score decreased to <8 (defined as control of symptoms), maintenance doses were begun. Daily maintenance dosing of 2 mglkglday allowed serum levels to decline at a desirable rate of 20% per day. These infants were more easily controlled and detoxified with the phenobarbital loading dose method than with previously accepted dosing regimens.
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Serial plasma levels of furosemide were measured in 14 premature newborns by high-pressure liquid chromatography following an intravenous dose of 1 m g / k g . All neonates were less than 21 days of age with birth weights ranging from 700 to 2500 grams. The half-life for furosemide calculated from the elimination rat constant was 19.95 t 3.0 hours (mean + s. err.) in these infants
The plasm clearance was determined to be 10.58 f 2.1 ml/kg/hour Equilibrium dialysis revealed nwre than 90% protein binding of furosemide bv the newborn. We previously reported that human growth hormone (hGtl) alters drug metabolism when administered to growth hormone deficient children. Six weeks of t.i.w. administration of 2U i.m. was found to increase half-life (tI2) of amobarbitdl from 1j.9 l~rs to 22.8 hrs. Further investigations on hGli deficient children were undertaken to elucidate the possible role of hGH in regulation of hepatic drug oxidation. Amobarbital was again chosen as i) representative substrate. Pharmacokinetic parameters (Vd, t i . C1) were determined on the basis of at least 3 blood level measurements following a single 3 -5 mglkg oral dose. In three children amobarbital was given before and 12 hrs after a single injection of 2U of hCH. No signiiicant change in Vd, ti or Cl was found. One subject was restudied at 6 weeks and found to have the characteristic prolongation of ti at that time. Two children were studied before and after 4 injections of hGH on altcrnate days. One showed no change in drug elimination; the other showed a very slight increase in t l > . All children who showed a prolongation at 6 weeks and who were restudicd 12 or more months later continued to have a long t'l. Conclusions: (1) The hGH inhibition of amobarbital metdbolism is reproducible (2) the effect is not evident at 2 weeks but is complete by 6 weeks, at least on current treatment schedules and (3) the
